Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study
Journal of Cancer · 01.07.2025 · 16 (10) · 3015-3023
DOI: 10.7150/jca.113815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer, erschienen am 01.07.2025. Verfasst von Martin Svaton und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
- Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland.
- Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine Pilsen, Charles University, Pilsen, Czech Republic.
- Department of Clinical Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovakia.
- Department of oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Zitieren
APA
Svaton, M., Knetki-Wroblewska, M., Hosek, P., Chowaniecova, G., Spacek, J., Fischer, O., Bilek, O., Hrnciarik, M., & Kauffmann-Guerrero, D. (2025). Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer, 16(10), 3015-3023. https://doi.org/10.7150/jca.113815
Vancouver
Svaton M, Knetki-Wroblewska M, Hosek P, Chowaniecova G, Spacek J, Fischer O, et al. Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer. 2025;16(10):3015-3023. doi:10.7150/jca.113815
BibTeX
@article{Svaton2025,
author = {Svaton, Martin and Knetki-Wroblewska, Magdalena and Hosek, Petr and Chowaniecova, Gabriela and Spacek, Jan and Fischer, Ondrej and Bilek, Ondrej and Hrnciarik, Michal and Kauffmann-Guerrero, Diego},
title = {Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study},
journal = {Journal of Cancer},
year = {2025},
volume = {16},
number = {10},
pages = {3015--3023},
doi = {10.7150/jca.113815}
}
EUVIMED